Chemistry:3C-FE

From HandWiki

3C-FE, also known as 4-(2-fluoroethoxy)-3,5-dimethoxyamphetamine or as 3C-fluoroescaline, is a serotonin receptor modulator of the phenethylamine, amphetamine, and 3C families.[1][2][3][4][5] It is the amphetamine (α-methyl) derivative of the psychedelic drug fluoroescaline (FE).[1][4][5]

According to Daniel Trachsel in his book Phenethylamine: von der Struktur zur Funktion and other publications, 3C-FE is inactive at doses of up to 24 mg orally, but has not been sufficiently investigated.[1][5] Hence, its properties and effects in humans remain unknown.[1][5][4]

The drug shows weak affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 5,987–12,000 nM and 8,400–>10,000 nM, respectively).[4][1][5] It is an agonist of the serotonin 5-HT2A and 5-HT2B receptors (EC50 (Emax) = 120 nM (102%) and 800 nM (29%), respectively).[5]

The chemical synthesis of 3C-FE has been described.[3]

3C-FE was first described in the scientific literature by Daniel Trachsel in 2002.[3][1][4]

See also

  • 3C (psychedelics)

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 (in de) Phenethylamine: von der Struktur zur Funktion. Nachtschatten-Science (1 ed.). Solothurn: Nachtschatten-Verlag. 2013. ISBN 978-3-03788-700-4. OCLC 858805226. https://books.google.com/books?id=-Us1kgEACAAJ. 
  2. The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. 1. Berkeley: Transform Press. 2011. ISBN 978-0-9630096-3-0. 
  3. 3.0 3.1 3.2 "Synthese von neuen (Phenylalkyl)aminen zur Untersuchung von Struktur-Aktivitätsbeziehungen, Mitteilung 1, Mescalin Derivate". Helvetica Chimica Acta 85 (9): 3019–3026. 2002. doi:10.1002/1522-2675(200209)85:9<3019::AID-HLCA3019>3.0.CO;2-4. 
  4. 4.0 4.1 4.2 4.3 4.4 "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis 4 (7–8): 577–590. 2012. doi:10.1002/dta.413. PMID 22374819. 
  5. 5.0 5.1 5.2 5.3 5.4 5.5 "Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines". Frontiers in Pharmacology 12. 2021. doi:10.3389/fphar.2021.794254. PMID 35222010.